Novartis Docket No. PAT051556-US-PCT01 Mofo Docket No. 223002100100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Dan M. GRANOFF et al.

Application No.: 09/701,453

Filing Date: (Intl.) May 28, 1999

For: COMBINATION MENINGITIDIS B/C

VACCINES

Examiner: S. J. N. Devi

Group Art Unit: 1645

Confirmation No.: 1041

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.98

MAIL STOP: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Application No.: 09/701,453

	rnis Supplemental ini	ormation Disclosure Statement is submitted:	
	With the application	With the application; accordingly, no fee or separate requirements are required.	
\boxtimes	Before the mailing	Before the mailing of a first Office Action after the filing of a Request for Continued	
	Examination under	Examination under 37 C.F.R. § 1.114. However, if applicable, a certification under 37	
	C.F.R. § 1.97 (e)(1)	C.F.R. § 1.97 (e)(1) has been provided.	
	Within three months	Within three months of the application filing date or before mailing of a first Office Action	
	on the merits; accord	on the merits; accordingly, no fee or separate requirements are required. However, if	
	applicable, a certific	ation under 37 C.F.R. § 1.97 (e)(1) has been provided.	
	After receipt of a first	After receipt of a first Office Action on the merits but before mailing of a final Office Action	
	or Notice of Allowance.		
	☐ A fee is requ	ired. Accordingly, a Fee Transmittal Form (PTO/SB/17) is attached to	
	this submissi	on.	
	A Certification	on under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is	
	believed to b	e due.	
	After mailing of a fir	After mailing of a final Office Action or Notice of Allowance, but before payment of the	
	Issue Fee.	Issue Fee.	
	☐ A Certification	on under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal	
	Form (PTO/S	SB/17) is attached to this submission.)	

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including Novartis Docket No. PAT051556-USPCT01 Mofo Docket No. 223002100100

extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **223002100100**.

Dated: November 8, 2010 Respectfully submitted,

Application No.: 09/701,453

By /Otis Littlefield/ Otis B. Littlefield

Registration No.: 48,751

MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105-2482 Telephone: 415.268.6846 Fax: 415.268.7522